Symbols

NTLA

Intellia·NASDAQ

--(--)

NTLA fundamentals

NTLA Q4 2025 Earnings

Intellia (NTLA) released its earnings on Feb 26, 2026: revenue was 23.02M (YoY +78.79%), beat estimates; EPS was -0.83 (YoY +34.65%), beat estimates.

Revenue / YoY

23.02M

+78.79%

EPS / YoY

-0.83

+34.65%

Report date

Feb 26, 2026

NTLA Earnings Call Summary for Q4,2025

ATTR Program Update: FDA lifted hold on MAGNITUDE-2 with safety modifications; MAGNITUDE remains on hold. lonvo-z Phase III enrollment complete, with 76% attack-free rate in early trials.
Financial Strength: $605M cash balance supports operations. lonvo-z's mid-single-digit market share could fund operations independently.
Safety Focus: <1% of ATTR patients experienced severe liver enzyme elevations; steroid regimen implemented to mitigate risk.
Commercial Momentum: Scaling teams for lonvo-z launch; 54% of U.S. HAE patients identified as potential candidates.

Earnings

EPS

Revenue

Revenue & Expenses

NTLA has released its 2025 Q4 earnings report, with revenue of 23.02M, reflecting a YoY change of 78.79%, and net profit of -95.79M, showing a YoY change of 25.69%. The Sankey diagram below clearly presents NTLA's revenue sources and cost distribution.

Key Indicators

Intellia (NTLA) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Intellia (NTLA)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Intellia (NTLA)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Intellia (NTLA)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown